Featured
User Blocked After Violation of Platform Policies
Gene Therapy Jul 20, 2026
Patient Briefs Jul 19, 2026
Gene Therapy Jul 18, 2026
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when...
Heart failure management is shifting as pharmacists take on a larger role. Discover how they...
Medicare introduces a $50 monthly copay for GLP-1 weight-loss drugs, offering affordable access to eligible...
Read our latest NF Research articles.
Explore the 2026 pulmonary embolism guidelines released by the American Heart Association and ACC, detailing...
Learn practical drink spiking prevention tips from pharmacists, including how OTC test strips work and...
Vision changes can happen gradually, making them easy to overlook at first. Many people assume...
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when CAR T‑cell treatment isn’t possible, with car
Bispecific antibodies are emerging immunotherapy for relapsed lymphoma and leukemia, offering a viable option when CAR T‑cell treatment isn’t possible,...
Bispecific therapy program by American Oncology Network offers safe outpatient dosing guidelines for community clinics, ensuring close monitoring and patient...
Heart failure management is shifting as pharmacists take on a larger role. Discover how they are improving outcomes for patients...
Proton pump inhibitors may reduce the benefit of durvalumab consolidation after chemoradiotherapy for unresectable stage 3 NSCLC, according to a...
GLP-1 receptor agonists can interact with oral chemotherapy, jeopardizing treatment effectiveness for diabetes and weight loss patients using glp-1 agents.
President Trump directs CMS to allocate $10 billion for rural health transformation under the One Big Beautiful Bill Act of...
New data on schizophrenia treatment options with subcutaneous olanzapine formulation show promise for people with schizophrenia.
Medicare introduces a $50 monthly copay for GLP-1 weight-loss drugs, offering affordable access to eligible beneficiaries starting July 2026.
FDA approves Leqembi home administration. Learn about the new starting dosage regimen for subcutaneous lecanemab treatment.
Explore the 2026 pulmonary embolism guidelines released by the American Heart Association and ACC, detailing severity categories and treatment strategies...